Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Articles published by FSD Pharma Inc.
< Previous
1
2
Next >
FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)
August 25, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201
July 17, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock
July 10, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors
July 04, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
June 30, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology
June 20, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors
May 25, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution
May 12, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari
May 11, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort
May 10, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
May 08, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis
April 17, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023
April 12, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Filing of Year-End 2022 Results
March 31, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors
March 30, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
March 22, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock
March 14, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board
February 28, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum
February 21, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements
February 15, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse
February 14, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate
February 07, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
January 30, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation
January 17, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Share Repurchase Program
January 13, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia
January 09, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023
January 06, 2023
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Changes to the Board of Directors
November 28, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari
November 10, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
September 29, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.